Mabwell Snaps Up China-First Approval For Xgeva Biosimilar
The Approval Opens Further Indications After Past Approval In Osteoporosis
Following the drug’s earlier approval as a biosimilar to Prolia, China’s regulators greenlighted the use of Mabwell’s denosumab as a substitute for the second branded version, Xgeva, in its indications.
